Be smarter and faster with PRO Alerts on BNIKF
$7.9B Non-Small Cell Lung Cancer Market: Just The Tip Of The Iceberg For Benitec's Tribetarna
- NSCLC market is forecast to be worth $7.9B by 2020.
- Benitec's Tribetarna pre-clinical studies shows substantial increases in survival rates.
- Tribetarna is an enhancement to standard chemotherapy, not a replacement for it.
- Tribetarna silences the TUBB3 gene which has been associated with chemotherapy resistance in NSCLC and many other cancers.
- The market for a TUBB3 gene silencing/chemo cancer therapy will be over $20B in 5-6 years time.
- The cost of health care has been forecast to escalate significantly.
- A change in the health care paradigm is required if health payers are to keep pace with the costs of disease standards of care.
- Benitec Biopharma is one company with the paradigm-changing technology that could be the answer to health payers' prayers.
- Early adopters of the new health care model, such as Benitec Biopharma, are set to corner the market for several major disease types.
- There is an opportunity for retail and corporate investors as big pharma may get the message and start investing in the new paradigm.
There are no Transcripts on BNIKF.
We currently have no Breaking News on this stock.
BNIKF vs. ETF Alternatives
Other News & PR